Pfizer Inc.
SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR
Last updated:
Abstract:
Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents. ##STR00001##
Status:
Application
Type:
Utility
Filling date:
24 Jun 2019
Issue date:
24 Oct 2019